L
Lipogems
Offers innovative adipose tissue solutions that improve recovery and provide a less invasive alternative to major surgery
About Lipogems
Lipogems International Spa is an Italian multinational biotechnology company based in Milan, specializing in regenerative medicine through its proprietary Lipogems® system. The company is recognized as a leader in processing adipose (fat) tissue to support the natural repair of damaged tissues caused by various pathologies, particularly in orthopedics and musculoskeletal disorders. The Lipogems® system offers a minimally invasive alternative or adjunct to traditional surgical interventions, utilizing a patient’s own adipose tissue, which is rich in mesenchymal stem cells and growth factors with regenerative properties.
The procedure involves a small incision to harvest adipose tissue, which is then processed to create micro-fragmented fat that can be injected into affected areas. This approach is designed to reduce pain and inflammation, improve tissue function, and promote healing, with most patients experiencing short recovery times and a rapid return to daily activities. Lipogems’ products have undergone extensive clinical testing and are used worldwide, with over 140 scientific publications supporting their efficacy and safety, including follow-ups of up to five years. The company collaborates closely with physicians, surgeons, and researchers to advance innovative medical solutions and improve patient outcomes globally.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Milan, Italy
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 60.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Tissue Engineering, Regenerative Medicine, ogr torino, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2022 | $14M | $55M | ABC Medtech · LIFTT | ↗ |
| SEED✓Equity / VC | Jul 2022 | $1.9M | $7.5M | LIFTT | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Lipogems is 1.6K monthly website visits, down 5.9% over the last three months. Lipogems's team declined 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
- AMABC Medtech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lipogems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lipogems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.